Genomic and Proteomic Tool Market Report 2025

The genomic and proteomic tool market size has grown rapidly in recent years. It will grow from $29.63 billion in 2024 to $33.14 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth during the historic period is driven by the rising prevalence of cancer and rare diseases, expansion of academic core laboratories, increased healthcare spending in high-income countries, standardization of clinical guidelines for molecular testing, and broader reimbursement for molecular diagnostics.

The genomic and proteomic tool market size is expected to see rapid growth in the next few years. It will grow to $51.2 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The projected growth in the forecast period is supported by aging populations increasing the chronic disease burden, integration of precision medicine into national health systems, expansion of payer coverage for biomarker testing, growth in clinical trials requiring molecular stratification, and adoption of value-based care rewarding targeted therapies. Key trends in this period include advancements in long-read DNA sequencing, higher-throughput single-cell RNA sequencing, spatial co-detection of RNA and proteins in situ, digital PCR for absolute quantification, and the use of trapped ion mobility spectrometry in proteomic analysis.

The growing adoption of personalized medicine is expected to drive the expansion of the genomic and proteomic tool market. Personalized medicine involves tailoring prevention, diagnosis, and treatment based on an individual’s molecular profile, which includes biomarkers derived from DNA, RNA, and proteins. This shift toward personalized approaches is largely fueled by advancements in genomics, proteomics, and biomarker discovery, which allow for treatments specifically designed around a person's genetic makeup. These innovations are boosting demand for targeted therapies, improved diagnostics, and more precise healthcare solutions. The role of genomic and proteomic tools is crucial in this process, as they help identify genetic variations and protein biomarkers, enabling clinicians to optimize treatments and enhance patient outcomes. For example, in February 2024, the Personalized Medicine Coalition and the FDA reported the approval of 16 new personalized treatments for patients with rare diseases, a significant increase from just six approvals in 2022. As a result, the rise in personalized medicine is fueling growth in the genomic and proteomic tool market.

Companies in the genomic and proteomic tools market are increasingly investing in spatial multi-omics technologies, which allow for the in-situ detection of RNA and proteins within the same cell, thereby integrating molecular data layers and preserving tissue architecture. This approach, known as spatial multi-omics, enables the measurement of gene expression and protein markers at single-cell or subcellular resolution, providing deeper biological insights than traditional single-modality tests. For instance, in August 2025, 10x Genomics, a US-based biotech company, launched Xenium Protein, a groundbreaking assay for single-cell RNA and protein analysis on the Xenium in situ platform. This solution simplifies workflows by eliminating the need for cross-platform data integration and comes with pre-validated protein subpanels for easier setup and quality control. These innovations enhance the ability to maintain spatial context while expanding biomarker panels for applications such as target validation, patient stratification, and mechanism-of-action studies.

In July 2024, Thermo Fisher Scientific Inc., a US-based biotech company, acquired Olink Holding AB to bolster its proteomics portfolio. This acquisition integrates Olink’s proximity extension assay (PEA) platform into Thermo Fisher’s Life Sciences Solutions segment, strengthening its capabilities in high-plex protein biomarker discovery and quantification. This acquisition complements Thermo Fisher’s existing mass spectrometry and sequencing technologies and accelerates progress in translational research and the development of companion diagnostics. Olink Holding AB, a company based in Sweden, is known for its next-generation proteomics tools and solutions.

Major players in the genomic and proteomic tool market are F. HoffmannLa Roche, Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton, Dickinson and Company, GE Healthcare, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bruker Corporation, Waters Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., PerkinElmer Inc., Promega, Novogene Corp., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California, Inc., Sophia Genetics, LC Sciences.

North America was the largest region in the genomic and proteomic tool market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in genomic and proteomic tool report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the genomic and proteomic tool market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Genomic and proteomic tools comprise advanced methods and technologies used to investigate the complete set of genes (genome) and proteins (proteome) in an organism. Genomic tools analyze DNA and RNA to explore gene sequences, expression patterns, mutations, and interactions, utilizing techniques such as DNA sequencing, PCR, microarrays, and genome editing. Proteomic tools focus on protein structure, function, abundance, and interactions through methods including mass spectrometry, 2D gel electrophoresis, and protein microarrays.

The primary product categories of genomic and proteomic tools include instruments, consumables, software, and services. Instruments are specialized devices designed to measure, detect, separate, or manipulate physical or molecular properties in laboratory samples, allowing precise observation and control beyond human capabilities, covering areas from microscopy to analytical measurement. The technologies involved include sequencing, microarrays, polymerase chain reaction (PCR), and chromatography, which operate through stages of sample preparation, library preparation, data analysis, and reporting. Applications extend to drug discovery, diagnostics, personalized medicine, agriculture, and animal research.

The genomic and proteomic tool market research report is one of a series of new reports that provides genomic and proteomic tool market statistics, including genomic and proteomic tool industry global market size, regional shares, competitors with a genomic and proteomic tool market share, detailed genomic and proteomic tool market segments, market trends and opportunities, and any further data you may need to thrive in the genomic and proteomic tool industry. This genomic and proteomic tool market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genomic and proteomic tool market consists of revenues earned by entities by providing services such as DNA sequencing systems, gene expression analysis platforms, microarray technologies, and mass spectrometry systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic and proteomic tools market also includes sales of electrophoresis equipment, and chromatography instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.